IFN-β can expand regulatory CD56bright NK cells in MS, and in vitro tests show that IFN-β and IFN-β plus corticosteroids increased the number of Ki-67+ NK cells in MS treatment [261]. The gene discussed is MKI67; the disease is myeloid sarcoma.